Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Medical Education, Sungkyunkwan University School of Medicine, Seoul, Korea.
Endocrinol Metab (Seoul). 2022 Jun;37(3):506-512. doi: 10.3803/EnM.2022.1429. Epub 2022 Jun 9.
Bone mineral density (BMD) testing is indicated for women aged 65 years, but screening strategies for osteoporosis are controversial. Currently, there is no study focusing on the BMD testing interval in Asian populations. The current study aimed to evaluate the estimated time interval for screening osteoporosis.
We conducted a study of 6,385 subjects aged 50 years and older who underwent dual-energy X-ray absorptiometry screening more than twice at Samsung Medical Center as participants in a routine health checkup. Subjects were divided based on baseline T-score into mild osteopenia (T-score, <-1.0 to >-1.5), moderate osteopenia (T-score, ≤-1.5 to >-2.0), and severe osteopenia (T-score, ≤-2.0 to >-2.5). Information about personal medical and social history was collected by a structured questionnaire.
The adjusted estimated BMD testing interval for 10% of the subjects to develop osteoporosis was 13.2 years in mild osteopenia, 5.0 years in moderate osteopenia, and 1.5 years in severe osteopenia.
Our study provides extended information about BMD screening intervals in Asian female population. Baseline T-score was important for predicting BMD screening interval, and repeat BMD testing within 5 years might not be necessary in mild osteopenia subjects.
骨密度（BMD）检测适用于 65 岁女性，但骨质疏松症的筛查策略存在争议。目前，尚无针对亚洲人群的 BMD 检测间隔的研究。本研究旨在评估筛查骨质疏松症的估计时间间隔。
我们对在三星医疗中心进行了两次以上双能 X 射线吸收法筛查的 6385 名 50 岁及以上的受试者进行了研究，这些受试者作为常规健康检查的参与者参加了研究。根据基线 T 评分，受试者分为轻度骨质疏松症（T 评分，-1.0 至>-1.5）、中度骨质疏松症（T 评分，≤-1.5 至>-2.0）和重度骨质疏松症（T 评分，≤-2.0 至>-2.5）。通过结构化问卷收集个人医疗和社会史信息。
调整后，10%的受试者发生骨质疏松症的估计 BMD 检测间隔为轻度骨质疏松症 13.2 年，中度骨质疏松症 5.0 年，重度骨质疏松症 1.5 年。
本研究为亚洲女性人群的 BMD 筛查间隔提供了更多信息。基线 T 评分对于预测 BMD 筛查间隔很重要，在轻度骨质疏松症患者中，重复 BMD 检测可能不需要在 5 年内进行。
